Email updates

Keep up to date with the latest news and content from Critical Care and BioMed Central.

Highly Accessed Letter

Vasopressin and terlipressin in adult vasodilatory shock

Angelo Polito1*, Emilio Parisini2, Zaccaria Ricci1, Sergio Picardo1 and Djillali Annane3

Author Affiliations

1 Department of Cardiology, Bambino Gesù Children's Hospital, Piazza S. Onofrio 4, 00165 Rome, Italy

2 Center for Nano Science and Technology @ POLIMI, Istituto Italiano di Tecnologia, Via G. Pascoli 70/3, Milano 20133, Italy

3 Critical Care Department, Hôpital Raymond Poincare (Assistance Publique-Hôpitaux de Paris), University of Versailles, Garches 92380, France

For all author emails, please log on.

Critical Care 2012, 16:470  doi:10.1186/cc11887


See related research by Serpa Neto et al., http://ccforum.com/content/16/4/R154

Published: 28 December 2012

First paragraph (this article has no abstract)

We have read with interest the study by Serpa Neto and colleagues showing that vasopressin use in vasodilatory shock is associated with reduced mortality [1]. However, we believe there are three aspects that need clarification.